Pregnancy‐associated plasma protein‐A and C‐reactive protein levels in pre‐eclamptic and normotensive pregnant women at third trimester

Deveci, Köksal; Söğüt, Erkan; Evliyaoğlu, Osman; Duras, Nuriye

doi:10.1111/j.1447-0756.2008.00835.x

Cited by 33 publications

(33 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in serum free β-hCG, which has vasodilatory properties, observed during and in the few weeks prior to the development of the clinical signs of PE, has been attributed to hypoxia-induced hypersecretion to counteract the generalized vasoconstriction which characterizes PE [10,11,12,13,39,40]. The reported paradoxical behaviour of serum PAPP-A in PE with decrease at 11-13 weeks and increase at the time of PE [4,14,15,16,17,18,19] could be the consequence of impaired placental function for the former and global activation of inflammation for the latter. Our finding that serum PAPP-A at 30-33 weeks is normal suggests that the increase in this metabolite does not precede but coincides with the clinical onset of PE.…”

Section: Discussionmentioning

confidence: 99%

“…There is also evidence that the altered levels of these metabolites may be apparent from the first trimester of pregnancy. Serum free β-hCG is increased in PE but at 11-13 weeks it is decreased or not altered [4,10,11,12,13,14], PAPP-A is increased in PE but reduced at 11-13 weeks [4,14,15,16,17,18,19] and PlGF is reduced in both established PE and in the first trimester [4,20,21,22,23,24,25,26]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia

Lai

Pinas²,

Poon

et al. 2013

Fetal Diagn Ther

View full text Add to dashboard Cite

Objective: To investigate the potential value of maternal serum concentrations of free β-human chorionic gonadotrophin (β-hCG), pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PlGF) at 30-33 weeks of gestation in the prediction of pre-eclampsia (PE) developing at or after 34 weeks. Methods: Serum free β-hCG, PAPP-A and PlGF were measured at 11-13 and at 30-33 weeks of gestation in a case-control study of 50 cases that developed PE at or after 34 weeks and 250 unaffected controls. The measured concentration of metabolites was converted into multiples of the unaffected median (MoM) and the MoM values in the PE and control groups were compared. Results: At 11-13 weeks, serum PlGF and PAPP-A, but not free β-hCG, were significantly lower in the PE group than in the controls (0.824, 0.748 and 0.857 vs. 1.000 MoM). At 30-33 weeks in the PE group, PlGF was reduced (0.356 MoM), free β-hCG was increased (1.750 MoM), but PAPP-A was not significantly different (0.991 MoM) from control (1.000 MoM). In screening for PE at 30-33 weeks by a combination of maternal characteristics and serum PlGF, the estimated detection rates, at a false-positive rate of 10%, of intermediate PE (requiring delivery at 34-37 weeks) and late PE (with delivery after 37 weeks) were 85.7 and 52.8%, respectively. The performance of screening was not improved by the addition of free β-hCG or the free β-hCG/PlGF ratio. Conclusion: Screening by maternal characteristics and serum PlGF at 30-33 weeks could identify most pregnancies that will subsequently develop PE.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia

Lai

Pinas²,

Poon

et al. 2013

Fetal Diagn Ther

View full text Add to dashboard Cite

show abstract

“…The insulin-like growth factor system is believed to play an important role in placental growth and development; it is therefore not surprising that low serum PAPP-A is associated with a higher incidence of PE. Increased level of maternal serum PAPP-A has been observed in established PE [80–82]. In chromosomally normal pregnancies there is evidence that low maternal serum PAPP-A in the first- and second-trimesters is associated with increased risk for subsequent development of PE.…”

Section: Screening By Maternal Biochemical Markersmentioning

confidence: 99%

Early Prediction of Preeclampsia

Poon

Nicolaides

2014

Obstetrics and Gynecology International

215

156

View full text Add to dashboard Cite

show abstract

“…There is increasing evidence that low levels of PAPP-A in the fi rst trimester are associated with adverse outcomes, such as preterm delivery, intrauterine growth retardation, preeclampsia, and stillbirth (4) . In the third trimester in preeclamptic pregnancies, PAPP-A is increased (5) .…”

Section: History Of Papp-a In Laboratory Medicinementioning

confidence: 99%

Pregnancy-associated plasma protein A: spotlight on kidney diseases

Kalousová

Tesař

Muravská

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Pregnancy-associated plasma protein A (PAPP-A) is a biomarker routinely used in screening for Down syndrome in the fi rst trimester of pregnancy. It is also present in very small amounts in men and non-pregnant women. PAPP-A is a key regulator of local insulin-like growth factor (IGF) bioavailability -IGFs are essential for normal body size during fetal development, but they are associated with aging and agerelated diseases. Measurement of circulating PAPP-A can provide valuable information not only in pregnant women (chromosomal anomalies and adverse pregnancy outcomes) but also in patients with coronary artery disease (contribution to diagnosis, prognostic value) and in patients with kidney diseases. PAPP-A is associated with renal function and proteinuria, is increased mainly in dialysis patients and decreases after kidney transplantation. It is an independent mortality predictor of hemodialysis patients and indicator of adverse outcome of transplanted patients. PAPP-A levels can be infl uenced by various chemicals and drugs, among them mainly heparin. Various assays for PAPP-A exist and the type of assay used in a study should be considered. This article reviews the data summarizing basic information about PAPP-A with a particular focus on the signifi cance of PAPP-A in renal diseases.

show abstract

Pregnancy‐associated plasma protein‐A and C‐reactive protein levels in pre‐eclamptic and normotensive pregnant women at third trimester

Abstract: We found higher levels of PAPP-A and CRP and the presence of a good correlation between CRP and MAP in pre-eclampsia.

Cited by 33 publications

References 27 publications

Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia

Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia

Early Prediction of Preeclampsia

Pregnancy-associated plasma protein A: spotlight on kidney diseases

Contact Info

Product

Resources

About